Repare Therapeutics

The CRISPR and Cas gene market was valued at $3.3 billion in 2023, with a CAGR of 20.38% since 2018. It's projected to reach $8.8 billion by 2028 and $24.6 billion by 2033. Growth drivers include personalized medicine, genetic disorders, and synthetic biology. Challenges include regulatory complexities and healthcare access in developing countries. The market is segmented by type, application, product type, end use, and service type, with various segments showing significant growth potential. North America leads the market, but Asia-Pacific and Africa are expected to grow fastest. The market is dominated by large players like Danaher Corporation and Agilent Technologies Inc.

Repare Therapeutics announced positive MYTHIC Phase 1 trial results for lunresertib and camonsertib in treating endometrial and platinum-resistant ovarian cancers, with plans for a Phase 3 trial in 2025. The company focuses on precision oncology using its SNIPRx platform.

Repare Therapeutics reports positive MYTHIC Phase 1 trial data for lunresertib and camonsertib combination, showing 25.9% ORR in endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Nearly half of gynecologic cancer patients maintained progression-free survival at 24 weeks. The company plans to initiate a Phase 3 trial in endometrial cancer in 2H 2025.

Repare Therapeutics reports positive MYTHIC Phase 1 trial results for lunresertib and camonsertib combination in endometrial and platinum-resistant ovarian cancers. The therapy showed favorable tolerability and efficacy, with plans for a Phase 3 trial in endometrial cancer starting in 2025.

Repare Therapeutics to host a conference call and live webcast on Dec. 12, 2024, at 4:30 p.m. ET to present data from its Phase 1 MYTHIC trial evaluating lunresertib in combination with camonsertib for platinum-resistant ovarian and endometrial cancers with specific gene mutations.

Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.

Repare Therapeutics announces a CRADA with NCI's CTEP to advance camonsertib, an ATR inhibitor, in cancer therapy. Camonsertib shows significant anti-tumor activity and is being tested in various clinical trials, including combinations with other treatments.

Repare Therapeutics reports financial results for Q3 2024, including data from ongoing clinical trials, plans for registrational trials in 2025, and positive safety results from Phase 1 trials. The company also dosed the first patient in a Phase 1 trial for a Polθ ATPase inhibitor and presented clinical benefits of camonsertib in combination with radiotherapy.